Cipla enlarges US footprint


Indian pharmaceuticals manufacturer Cipla has agreed to purchase two US generics companies for US$550 million. Through its UK arm – Cipla EU – it will fork out US$500 million to take control of InvaGen Pharmaceuticals and US$50 million for Exelan Pharmaceuticals in an all-cash transaction. The deal will give Cipla a foothold in the US generics market through cardiovascular, anti-infective, diabetes and other generics.

The deal is one of the biggest overseas purchases by an Indian pharmaceutical player and is expected to close by the end of the year.

You must be a subscriber to read this content, or you can register for free to enjoy the current issue.